The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?
In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years.
“Five years after the initial accelerated approval, you should have a definitive answer,” said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. “Thousands of people are getting those drugs. That seems a mistake if we don’t know whether they work or not.”
The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs.
It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce better evidence before gaining full approval.
Elon Musk gets approval from FDA to implant his Neuralink brain chip into a second patient
Arrest Lord Mountbatten's self
Dali cargo ship is finally brought back to port
Online reading or offline clubs? Young Chinese embrace both in digital era
Trump or Biden? Either way, US seems poised to preserve heavy tariffs on imports
Seven sneaky clauses in estate agent contracts that can cost you dear
Trump or Biden? Either way, US seems poised to preserve heavy tariffs on imports
DR MARTIN SCURR: How losing your hearing may cause dementia
Queen Camilla reveals she's seen the first season of Bridgerton
Key evidence in the 'burking' murder trial was 'hidden' from defence lawyers
Storms damage homes in Oklahoma and Kansas. But in Houston, most power is restored
Strictly star Nadiya Bychkova reveals she doesn't know if she's on the show's 2024 line